Canaccord lowered the firm’s price target on AtriCure (ATRC) to $52 from $66 and keeps a Buy rating on the shares. The firm updated its model folloing the company’s Investor Day that both reiterated its 2025 guidance and provided an aspirational LRP that included three-year objectives as well as targets for 2030.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC: